SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention as it expands across multiple chains like Solana, BNB, and Base. Community members highlight its fully circulated supply and deflationary burn mechanism, contributing to its increasing popularity. Traders are watching its growing presence on various exchanges, with some suggesting it could be the next big meme coin.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as analysts adjust price targets and ratings, following news of Piper Sandler and Stephens & Co. setting overweight ratings. The community highlights potential for new store openings and expansion into electric vehicle services, viewing it as a safe, long-term investment. Bullish sentiment suggests potential to test all-time highs, with some eyeing it as an 'easy money' opportunity.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community discusses its potential, particularly following integrations with Abstract Chain and Shogun, which enable new functionalities like cross-chain triggers and AI-driven DeFi automation.  Enthusiasm centers around the project's technology and speculation about future listings, along with anticipation for the sunsetting of $PRQ, which some believe is currently limiting REACT's price action. Some community members express very high hopes for the token.

Hasbro, Inc. engages in the provision of children and family leisure time products and services with a portfolio of brands and entertainment properties. The firm's brands of toys include Power Rangers, Magic: The Gathering, Monopoly, My Little Pony, Nerf, Play-Doh and Transformers. It operates through the following segments: Consumer Products, Wizards of the Coast and Digital Gaming, Entertainment, and Corporate and Other. The Consumer Products segment markets and sells toys and game products around the world. It also promotes brands through the out-licensing of trademarks, characters and other brand and intellectual property rights to third parties, and through the sale of branded consumer products such as toys and apparel. The Wizards of the Coast and Digital Gaming segment promotes the company's brands through the development of trading cards, role-playing and digital game experiences based on Hasbro and Wizards of the Coast properties. The Entertainment segment develops and distributes entertainment content including film, scripted and unscripted television, children's programming, digital content, and live entertainment. The Corporate and Other segment includes the management and administrative services to its principal reporting segments. The company was founded by Henry Hassenfeld and Hilal Hassenfeld in 1923 and is headquartered in Pawtucket, RI.

Hasbro, Inc.

Hasbro ($HAS) is trending due to unusual options activity signaling bullish sentiment and upcoming earnings, particularly driven by the performance of Magic: The Gathering. Community members are discussing the potential impact of the Lord of the Rings set and digital gaming growth on Hasbro's financials. As a consumer discretionary stock, Hasbro is also being considered in light of potential Fed rate cuts.

ProShares Trust - ProShares VIX Mid-Term Futures ETF

ProShares VIX Mid-Term Futures ETF

VIXM is trending as traders discuss potential government shutdowns and the accumulation of volatility insurance amid frothy market conditions. Community members are exploring VIXM leaps and comparing it to other volatility hedges like $VIXY, noting its potential for minimal decay and suitability for longer holding periods. Some traders suggest VIXM could be a strategic play given historical patterns of increased volatility in October.

SSgA Active Trust - Health Care Select Sector SPDR

Health Care Select Sector SPDR Fund

XLV is trending as traders discuss sector rotation into healthcare, driven by defensive plays and a potential safe haven amid market uncertainty. Community discussions also mention the implications of Rite Aid store closures and CVS's potential earnings run-up. Additionally, there's ongoing analysis regarding technical indicators, tariff impacts, and large investors making moves in the healthcare space.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is trending amid discussions around a major CalPERS contract win, taking over prescription drug benefits from UnitedHealth's OptumRx, highlighting CVS's focus on affordability and transparency. Community members are also discussing the company's attractive dividend and moat, positioning it as a defensive play in the healthcare sector. Additionally, potential PBM regulations and their impact on CVS are being actively debated.

Green Satoshi Token

GSTSOL is trending as traders discuss its potential for a significant breakout, with some pointing to its low market cap and historical price movements as indicators for a possible surge. Community members are actively monitoring volume and chart patterns, speculating about a potential pump and looking for signs of increased buying pressure. Some users suggest the STEPN app could drive future token demand.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending as the community discusses its potential for growth and real-world applications, especially in light of recent developments in the broader crypto market. A key point of discussion revolves around whether HBAR can compete with other cryptocurrencies and secure partnerships. Community members are also analyzing price movements and anticipating future catalysts.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN Crypto is trending as Horizen invites the community to test migration to the Base chain, aiming for enhanced security and usability within Ethereum's ecosystem; community members are actively discussing price targets and potential breakouts, while some express concerns about price drops, others anticipate a significant move upward.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Families are asking a U.S. appeals court to revive lawsuits against Kenvue and retailers that sold acetaminophen, alleging Tylenol and generic versions of the drug caused autism and ADHD in children, and pointed to U.S. President Donald Trump’s recent advice that pregnant women avoid the pain reliever.<a href="https://stocktwits.com/symbol/KVUE">Shares of Kenvue</a> closed Wednesday down 2.2% at $16.86, before edging up 0.8% in after-hours trading.Lawyer Ashley Keller, representing the families, notified the 2nd U.S. Circuit Court of Appeals on Wednesday of the administration’s position, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/government/attorneys-urge-court-overseeing-tylenol-autism-lawsuits-consider-trump-2025-09-25/">report</a>.At a White House press event two days earlier, Trump, along with FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr., highlighted research by Harvard public health dean Andrea Baccarelli, one of the plaintiffs’ experts.More than 500 lawsuits against Kenvue and retailers were dismissed last year by U.S. District Judge Denise Cote in Manhattan, who concluded the expert testimony lacked reliable methods and relied on selective analysis. The appeals court is scheduled to hear arguments on Oct. 6.Kenvue said regulators have not confirmed any link between acetaminophen and autism, adding that it expects the litigation to fail. Legal experts said it would be unusual for the appeals court to give much weight to the administration’s actions or Trump’s comments in deciding how to proceed with the cases.Separately, South Korea’s drug regulator said it would seek information from companies following Trump’s remarks, though it added the U.S. announcement “contained little substance.” The FDA also said it would not ban acetaminophen but will add a pregnancy-related autism warning to labels while stressing no causal link has been proven.Studies have shown conflicting results. A 2024 Swedish study involving 2.5 million children found no causal connection, while a 2025 review of 46 prior studies, co-authored by Baccarelli and colleagues from Mount Sinai and Harvard, suggested a potential association but stated that causation could not be proven.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 186% jump in 24-hour message volume.“I’d guess pregnant women make up a small portion of total Tylenol consumption,” said one user. “Great opportunity to buy at a discount. Will get paid the dividend while the market takes its time to think about this one.”<stembedurl>https://stocktwits.com/wildwood10/message/629884537</stembedurl>Another user reported buying shares at $16.63 for a long-term dividend portfolio and was watching to see if the price dropped further or if that day marked the low.<stembedurl>https://stocktwits.com/Sir_White/message/629891850</stembedurl>Kenvue’s stock has declined 18.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Stock To Face More Headwinds? Trump’s Tylenol Warning Revives Autism Lawsuits, Retail Bulls Stay Unfazed

More than 500 lawsuits over Tylenol and autism were dismissed last year, but families are now appealing to the 2nd U.S. Circuit Court of Appeals, which is scheduled to hear arguments on Oct. 6.

Equity

Kenvue shares traded 2.5% higher in premarket on Wednesday as investors took comfort from reassurances by global health agencies that Tylenol remains safe, with no new evidence linking its use in pregnancy to autism.&nbsp;South Korea’s drug regulator said it would seek information from companies after U.S. President Donald Trump’s comments linking Tylenol to autism.&nbsp;"Since the U.S. government’s announcement contained little substance, we have no additional comments," Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/south-koreas-drug-watchdog-review-us-tylenol-claim-2025-09-24/">reported</a>, citing South Korea's food and drug safety ministry.The news follows a rebound on Tuesday when Kenvue rose 1.6% in regular trade and another 0.8% after hours. That rally came after the U.S. Food and Drug Administration stopped short of banning acetaminophen and instead announced it will add a pregnancy-related autism warning to product labels while alerting physicians nationwide. The FDA noted that no causal link has been established between the two.Despite the FDA’s caution, plaintiffs’ lawyers said the label change could revive litigation that was dismissed by a federal court last December. Citi said the legal risks appear to be limited, while Evercore ISI cut its price target to $18. Barclays said the recent selloff looks overdone even in the unlikely event of U.S. acetaminophen sales being reduced to zero.Kenvue, led by interim CEO Kirk Perry, is already facing slowing sales, pressure from activist investors, and a review of its brand portfolio that could result in divestitures of its smaller skincare lines.&nbsp;Tylenol remains its largest brand and contributes a mid-to-high single-digit share of revenue. Analysts warn the FDA’s move could erode consumer trust and weigh on demand, especially among pregnant women, while also creating confusion for patients who need fever treatment during pregnancy.The situation is being described as Kenvue’s most serious reputational challenge since the Tylenol cyanide poisonings of the 1980s.On Stocktwits, retail sentiment for Kenvue was ‘bullish’&nbsp;heading into Wednesday’s session, following a 270% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kenvue company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Is Kenvue Stock Rising Premarket Today?

South Korea’s drug regulator said it will seek information from companies following U.S. claims about Tylenol and autism.

U.S. stocks retreated on Tuesday, snapping a three-session winning streak, as profit-taking in some of the tech stocks that had run up significantly generated selling pressure. Consumer discretionary and IT stocks primarily served as drags, although energy and real estate stocks recorded notable gains.After the market eased off its highs, the following stocks saw brisk trading activity in the extended session:Nvidia Corp. (NVDA)After-hours move: 0.28%Trading volume: 8.88 million<a href="https://stocktwits.com/symbol/NVDA">Nvidia’s stock</a> retreated 2.82% to $178.43 on Tuesday, following its nearly 4% rally in the previous session, which was driven by an announcement regarding a potential investment of up to $100 billion in artificial intelligence (AI) startup OpenAI.&nbsp;The retreat came amid profit-taking, as traders weighed in on Nvidia’s investments. On Tuesday, DA Davidson analyst Gil Luria expressed concerns that Nvidia could become an “investor of last resort,” bailing out CoreWeave, Intel, and now OpenAI, according to excerpts of the note made available by Fly.The analyst said he would have preferred more traditional investors to step up and fund the data center buildout.On Stocktwits, retail sentiment toward Nvidia stock remained ‘bullish’ as of late Tuesday, with message volume, however, at ‘normal’ levels.The stock has gained nearly 33% this year.Plug Power (PLUG)After-hours move: -4.74%Trading volume: 11.61 millionAfter declining 4.5% in Tuesday’s regular session,&nbsp;<a href="https://stocktwits.com/symbol/PLUG">Plug Power stock</a> fell sharply yet again in the after-hours. The stock initially jumped on Tuesday morning as the hydrogen fuel cell energy company’s announcement regarding hosting Oppenheimer at its Georgia plant excited investors. Alongside the announcement, the company stated that the facility achieved a record August performance, producing 324 metric tons of green hydrogen.The upward momentum could not be sustained as a nine-session winning streak in the stock prompted some traders to take profits.Retail sentiment toward Plug Power stock continues to remain ‘extremely bullish’ (92/100), and the message volume was ‘extremely high.’For the year-to-date period, the stock has increased by approximately 19%.Micron Technology, Inc. (MU)After-hours move: +0.44%Trading volume: 11.83 millionMemory chipmaker Micron reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-hardly-budges-after-ai-fueled-q4-beat/chDKV1YR3dI">forecast-beating results</a> for the fourth quarter of the fiscal year 2025, and issued upbeat guidance for the current quarter. The stock showed a muted reaction to the strong print.<a href="https://stocktwits.com/symbol/MU">Micron stock</a>, which has nearly doubled this year, elicited ‘extremely bullish’ sentiment (93/100) from among the retail users of Stocktwits. The message volume on the stream was also ‘extremely high.’Kenvue, Inc. (KVUE)After-hours move: +0.95%Trading volume: 7.17 millionKenvue remained on traders’ radar as the company’s stock rebounded from its all-time low. The stock came under pressure on Tuesday after President Donald Trump crusaded against the company’s best-selling iconic brand Tylenol, alleging that it caused autism and urging pregnant&nbsp;women not to consume it.With the medical and scientific community refuting the allegations and Wall Street firms estimating that the company would experience no severe impact from the entire episode, the stock rebounded by over 1.5% on Tuesday.&nbsp;Stocktwits retail traders’ sentiment tempered slightly to ‘bullish’ (61/100) as of late Tuesday from the ‘extremely bullish’ mood seen a day ago. The message volume continued to stay ‘extremely high.<a href="https://stocktwits.com/symbol/KVUE">Kenvue stock&nbsp;</a>has lost about 17% YTD.Kroger Co. (KR)After-hours move: unchangedTrading volume: 5.43 millionRetailer and supermarket operator Kroger (KR) saw its stock rise 1.29% on Tuesday despite the broader market pullback.&nbsp;<a href="https://stocktwits.com/symbol/KR">Kroger’s stock</a> has gained 8.5% so far this year. Last week, Argus increased its price target for Kroger stock by $1 to $85, citing the retailer’s innovative and increasingly affordable brands, strong private brands, growing emphasis on fresh food, and its strong customer analytics that help deliver personalized discounts to customers, according to The Fly.Retail sentiment toward the stock turned to ‘neutral’ (50/100) by late Tuesday from ‘bearish’ a day ago, while the message volume stayed at ‘low’ levels.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-lithium-americas-stock-jump-after-hours-today/chDKnOJR3dB">Why Did Lithium Americas Stock Jump After-Hours Today?</a>

Traders work on the floor of the New York Stock Exchange (NYSE) on September 03, 2025, in New York City. 

Nvidia, Plug Power, Micron, Kenvue, Kroger: What Sparked Heavy After-Hours Trading In These 5 Stocks?

Micron stock showed a muted reaction to earnings despite the quarterly numbers and guidance exceeding expectations.

U.S. President Donald Trump’s caution against Tylenol has reignited scrutiny of Kenvue, just as the U.S. FDA moves to add pregnancy-related autism warnings to acetaminophen labels and has alerted physicians nationwide.&nbsp;Although the agency acknowledged that no causal link has been established, plaintiffs’ lawyers say the new language could revive litigation dismissed by a federal court last December, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-23/tylenol-maker-kenvue-faces-mounting-crisis-after-trump-s-rebuke">report</a>.&nbsp;The heightened risk comes as Kenvue, under interim CEO Kirk Perry, faces weak sales, activist investor demands, and a portfolio review. Tylenol, its largest brand, contributes a mid- to high-single-digit share of revenue.&nbsp;Despite the legal overhang, Kenvue’s stock shrugged off concerns, rising 1.6% in regular trade and another 0.8% after hours on Tuesday. Investors took comfort in the fact that the FDA stopped short of a ban and that no new scientific evidence was presented.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-kenvue-stock-rising-today/chDhDbOR350">Citigroup said it sees limited legal risk</a> and expects shares to trade higher, while Evercore ISI cut its price target to $18. Barclays argued that the recent selloff looks overdone, even under highly unlikely worst-case scenarios.The move may also mark Kenvue’s biggest reputational test since the 1980s Tylenol cyanide poisonings, with concerns&nbsp;that it could create confusion for patients who need to treat fevers during pregnancy.Plaintiffs’ lawyer Mark Lanier said the FDA move breathes new life into lawsuits, while legal experts noted courts rarely overturn the agency’s risk assessments. Kenvue stated that the claims lack both legal and scientific merit. Johns Hopkins professor Stacey Lee said even without proving causality, the label could be powerful evidence before juries.The company has been unsettled since its 2023 spin-off from Johnson &amp; Johnson. Former CEO Thibaut Mongon struggled to stabilize operations, prompting pressure from activist hedge funds Starboard Value, TOMS Capital, and Third Point. Kenvue responded by naming Perry interim CEO, adding Starboard’s Jeffrey Smith to its board, and&nbsp;considering the sale&nbsp;of smaller skincare brands, such as Neutrogena.The business faces a&nbsp;challenging consumer backdrop of inflation, high interest rates, and weaker demand, which has led to two consecutive quarters of declining organic sales and a reduction to its full-year forecast.&nbsp;On Stocktwits, retail sentiment for Kenvue was ‘bullish’ amid a 270% surge in 24-hour message volume.One user pointed out that no direct causal link between pregnancy and autism has been established and described the stock as a “huge buying opportunity,” adding that they bought shares after hours and expect it to soon reach $21.<stembedurl>https://stocktwits.com/Mukulu2025/message/629750922</stembedurl>Another bullish user called Kenvue a “great investment opportunity.”<stembedurl>https://stocktwits.com/Little_thebodyguard/message/629750599</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

Kenvue (KVUE) shares jumped nearly 4% in early trading on Tuesday and became the top trending ticker on Stocktwits after Citigroup stated that it sees limited legal risk for the company following President Donald Trump's discouragement of pregnant women from taking Acetaminophen, the active ingredient in Tylenol.Citi maintained a ‘Neutral rating on the stock with a $20 price target, according to TheFly. Citi expects Kenvue shares to trade higher on Tuesday, following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.The firm stated, however, that there could be a risk associated with Tylenol consumption due to the negative headlines.Retail sentiment on <a href="https://stocktwits.com/symbol/KVUE">Kenvue</a> jumped to ‘extremely bullish’ from ‘neutral’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits. The retail user message count on the stock increased by 1,860% in the last 24 hours on Stocktwits, as of Tuesday morning.Evercore ISI lowered the firm's price target on Kenvue to $18 from $23 and maintained an ‘In Line’ rating after FDA commissioner Marty Makary announced the start of a process to change the safety label on Acetaminophen. This is to suggest a potential link between its use and an increased risk of neurological conditions such as autism. Barclays analyst Lauren Lieberman noted that the Trump administration's views on the links between Tylenol and autism are contrary to the mainstream medical establishment. The firm's "rough math" suggests that Kenvue's 17% selloff since September 4 is overdone, even in the "highly-unlikely scenario" that its U.S. Acetaminophen business is reduced to zero.Shares of Kenvue have declined nearly 24% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-to-close-its-amazon-fresh-uk-stores/chDhwyFR35L">Amazon To Close Its ‘Amazon Fresh UK’ Stores</a>

Why Is Kenvue Stock Rising Today?

Citi noted that Kenvue shares would be trading higher on Tuesday following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.

Tylenol manufacturer Kenvue, Inc.‘s (KVUE) battered stock appears on track to rebound from Monday’s ravages inflicted by President Donald Trump's suggestion at a White House press conference that the usage of the iconic brand causes autism.The president said Tylenol "is no good" and that pregnant women should "fight like hell" only to take it in cases of extreme fever.<a href="https://stocktwits.com/symbol/KVUE">Kennvue stock,</a> which fell 7.47% on Monday to a record low, was last seen rising nearly 6% in premarket trading. The rebound comes after the company, a spin-off of Johnson &amp; Johnson, and experts refuted Trump’s claims.&nbsp;The company reportedly&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.axios.com/2025/09/22/trump-tylenol-autism-announcement-kenvue">said</a> in a statement that “acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy.” Acetaminophen&nbsp;is the base ingredient for Tylenol.“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for&nbsp;expectant mothers."A separate Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-maker-kenvue-shares-bounce-trump-claims-face-pushback-2025-09-23/">stated</a> that Citi analysts expected the stock to recover from the sell-off on Monday. “Overall, we see limited judicial risk following today's announcement, but there could be some impact on Tylenol consumption due to negative headlines,” they said.This should alleviate investor concerns about the company facing a barrage of lawsuits over the alleged adverse effects of Tylenol.The report also noted that many doctors disagreed with the Trump administration’s Tylenol claims and warned that these unfounded claims&nbsp;would likely impair maternal health.Eric Liang Feigl-Ding, an American public health scientist, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrEricDing/status/1970238664169885774">said </a>on X that "RFK Jr and Trump are wrong—the largest &amp; best study in the world in 2.5 MILLION KIDS—found no increased autism risk with acetaminophen (aka paracetamol, Tylenol) use by the mother during pregnancy.""A crude unadjusted analysis found only a preliminary 5% risk, but once you adjust for family by matching using sibling controls (who didn’t get autism), the even tiny 5% risk vaporizes to 0%."On Stocktwits, retail sentiment toward Kenvue stock flipped to 'extremely bullish' (92/100) by early Tuesday from 'bearish' a day ago, and the message volume was 'extremely high.'<figure class="image"><img style="aspect-ratio:628/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_5_59_12_AM_png_e85794a3af.webp" alt="Screenshot 2025-09-23 at 5.59.12 AM.png" width="628" height="57"><figcaption>KVUE sentiment and message volume as of 6 a.m. ET, Sept. 23 | source: Stocktwits</figcaption></figure>Kenvue stock is down more than 21% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/applied-materials-gets-price-target-boost-while-analyst-turns-cautious-on-lam-research/chDhqaKR3PD"> Applied Materials Stock Gets Price-Target Boost While Analyst Turns Cautious On Lam Research: Here’s Why</a>

In this photo illustration, a Tylenol caplet is displayed on September 22, 2025, in San Anselmo, California. 

Kenvue On Track To Bounce Back From Record Lows — What’s Driving Stock Higher In Premarket?

Many doctors reportedly disagreed with the Trump administration’s Tylenol claims and warned that these unfounded claims would likely impair maternal health.

Shares of Johnson &amp; Johnson held up better than its consumer spinoff, Kenvue, on Monday after U.S. President Donald Trump linked autism to Tylenol and childhood vaccines, claims that decades of scientific research have not supported.&nbsp;J&amp;J shares slipped 1.1% to $174.21 in regular trade before gaining 0.5% after hours. Meanwhile, Kenvue fell 7.5% to a record low at $16.97 before rebounding 4.4% in late trading.&nbsp;Guggenheim upgraded J&amp;J to ‘Buy’ from ‘Neutral’ with a raised price target of $206 from $167, which implies an upside of 18% from J&amp;J’s closing price on Monday.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kenvue-stock-hits-record-low-trump-urges-pregnant-women-fight-like-hell-against-tyleno/chDhg0tR3PR">Trump’s sharp warnings against acetaminophen</a>, the active ingredient in Tylenol, directly pressured Kenvue, while J&amp;J moved lower more modestly, supported by its diversified portfolio and pipeline updates.Johnson &amp; Johnson has also remained a defensive play for income investors. The company went ex-dividend on Aug. 26, with its most recent quarterly payout made on Sept. 9, underscoring its steady record of shareholder returns even as sector peers face volatility.Earlier this month, Josh Brown, CEO of Ritholtz Wealth Management, told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/16/josh-browns-best-stocks-in-the-market-johnson-johnson.html">CNBC</a> that J&amp;J’s transformation into a pure-play healthcare company after spinning off Kenvue, coupled with a pipeline focused on oncology, immunology, neuroscience, and medtech, is helping steady sentiment. He noted the stock has been “building a base” for years and could be on the verge of a breakout if it clears long-term resistance.The company also drew attention in the U.S. Psychiatric and Mental Health Congress, where it released Phase 3 data for its investigational depression treatment seltorexant on Monday. The trial showed the drug has efficacy similar to that of quetiapine XR, a frequently used adjunctive therapy, but was well-tolerated with&nbsp;fewer adverse events like drowsiness and weight gain.&nbsp;While it did not hit its primary target, seltorexant was still better tolerated as measured by a higher completion rate at week 26, supporting its use in patients with major depressive disorder who are still suffering from insomnia symptoms.On Friday, J&amp;J also said the FDA approved a subcutaneous induction regimen of Tremfya for adults with ulcerative colitis, making it the first IL-23 inhibitor to offer both SC and IV induction options for UC and Crohn’s disease, which&nbsp;affects about 3 million Americans.&nbsp;On Stocktwits, retail sentiment&nbsp;for JNJ,&nbsp;however, was ‘extremely bearish’ amid&nbsp;a 1,720% spike in 24-hour message volume. One user said J&amp;J could still face billions in liability from Tylenol autism suits despite Kenvue assuming primary responsibility after the 2023 spin-off, especially when combined with ongoing talc cases.&nbsp;<stembedurl>https://stocktwits.com/StormChaser/message/629585491</stembedurl>Another&nbsp;user jokingly remarked that with more than 66,000 talc plaintiffs and fresh Tylenol claims, J&amp;J might soon “own the largest law firm in the world.”<stembedurl>https://stocktwits.com/Suite510/message/629583920</stembedurl><a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson’s stock</a> has risen 23.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Johnson and Johnson American multinational of medical, pharmaceutical and perfumery products headquartes on 28 January 2025 in Madrid, Spain.

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

U.S. President Donald Trump on Monday linked autism to both childhood vaccines and the use of Tylenol by pregnant women and children, claims that decades of scientific research have not supported.&nbsp;Meanwhile, Kenvue, the maker of Tylenol, rejected the claims. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trump-expected-link-autism-with-tylenol-experts-say-more-research-needed-2025-09-22/">report</a>, citing a company statement.&nbsp;Kenvue, which was spun off from Johnson &amp; Johnson in 2023, saw its shares fall 7.5% during Monday’s session to a record low before recovering 4.4% in extended trading.In a White House news conference, Trump repeatedly advised women and parents not to use the painkiller, saying, “Don’t take Tylenol. Fight like hell not to take it,” while acknowledging he was not a doctor.Standing alongside Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, Trump also called for a reexamination of vaccine schedules, urging separate measles, mumps, and rubella shots, and stating that the hepatitis B vaccine should not be administered until age 12, despite longstanding medical guidance recommending it within 24 hours of birth.&nbsp;Tylenol is Kenvue's largest brand, accounting for a mid-to-high single-digit percentage of total sales, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-autism-report-announcement-eb7c90c8?mod=hp_lead_pos1">noted</a>, citing Morningstar. Trump’s warning also comes as Kenvue continues to face litigation over acetaminophen, with hundreds of lawsuits alleging a link to autism or ADHD currently under appeal after a federal judge last year ruled the scientific evidence unreliable.Meanwhile, acetaminophen remains an important option for pregnant women, and vaccines have saved millions of lives, with UNICEF estimating at least 154 million lives preserved over the last 50 years.The Trump administration also announced steps to position leucovorin, a form of folic acid currently used in chemotherapy support, as a treatment for autism-related symptoms.&nbsp;The FDA approved a version of the drug from GSK and cited a review of 40 patients with cerebral folate deficiency, a rare metabolic disorder linked to neurological symptoms. Medicaid coverage for leucovorin will be extended to autism patients, with expectations that private insurers will follow.Researchers reiterated that there is no solid evidence that acetaminophen causes autism. A 2024 study using 2.5 million Swedish children found no causal relationship. In 2025, a review of 46 previous studies was done, which found an association, but it does not show cause and effect.&nbsp;Researchers advised that pregnant women who need acetaminophen should continue taking it at the lowest dose and for the shortest time. Bigger, randomized trials are still needed to determine leucovorin's potential.On Stocktwits, retail sentiment for Kenvue was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said the administration’s comments unfairly singled out Kenvue as if Tylenol were the only acetaminophen brand on the market, adding that people weren’t about to stop using the drug for everyday needs and calling the concerns overblown.<stembedurl>https://stocktwits.com/FatherofTrades/message/629593979</stembedurl>Another user said that they were buying every dip in Kenvue shares and planned to hold through the lawsuits and any eventual settlement.<stembedurl>https://stocktwits.com/StockCapture/message/629592908</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 18.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.

Shares of Kenvue slumped 6% on Monday afternoon following reports that the Trump administration is expected to unveil efforts exploring how Tylenol's active ingredient may be linked to autism.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.washingtonpost.com/health/2025/09/21/trump-autism-announcement-tylenol-leucovorin/">reported</a> on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol. They plan to warn pregnant women against using Tylenol early or unless they have a fever, sources told WSJ.Officials also intend to tout a drug called Leucovorin as a potential autism treatment, the report said. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.White House press secretary Karoline Leavitt, however, urged people to await an announcement today from President Trump at a press briefing.“...before you jump to conclusions based on reports that the White House has not even confirmed, I would encourage everyone in this room to go into the four o'clock announcement with some critical thinking skills and with some open ears to actually listen to what the President and his team of outsiders have to say about this. And there will be a number of things that will be announced and discussed,” she said.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. It is widely used as a pain reliever, including by pregnant women.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_2_12_39_PM_png_4b40cf5a25.webp" alt="KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="574" height="61"><figcaption>KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Trump, speaking at a memorial for conservative activist Charlie Kirk on Sunday, also touted a big announcement pertaining to autism. “Tomorrow we’re going to have one of the biggest announcement[s] … medically, I think, in the history of our country,” he said, as reported by WSJ. “I think you’re going to find it to be amazing. I think we found an answer to autism.”Earlier this month, it was reported that Kenvue Inc. reportedly <a href="https://stocktwits.com/news-articles/markets/equity/tylenol-kenvue-met-rfk-jr-to-keep-off-autism-list/chw8MshRdDV">met</a> with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” Kenvue <a href="https://stocktwits.com/news-articles/markets/equity/kenvue-jnj-retail-traders-cautious-as-health-officials-plan-to-announce-tylenol-links-to-autism/chDQOxLR3cI">told</a> WSJ in a statement. Autism spectrum disorder (ASD) is a complex developmental condition involving persistent challenges with social communication, restricted interests, and repetitive behavior.KVUE stock is down by 20% this year and by about 25% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kenvue Shares Drop Ahead Of Trump’s ‘Biggest Announcement’ On Autism: Reports Say Administration To Link Tylenol With Risk Of Disease

The Wall Street Journal reported on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol.

The U.S. government is widely expected to link Tylenol to autism, advising pregnant women against its use, Monday, according to media reports. The development is keeping retail investors on the edge for its maker, Kenvue, and associated company Johnson &amp; Johnson, according to Stocktwits data.Tylenol is an acetaminophen-based over-the-counter medicine for reducing pain, allergies, cold, and fever. The popular tablets are produced, marketed, and sold by Kenvue, which spun off from J&amp;J in 2023,&nbsp;and rake in about $1 billion annually, a high-single-digit percentage of the firm’s total revenue,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.morningstar.com/stocks/kenvue-stock-tumbles-kennedys-pending-report-tylenol-autism">according</a> to a Morningstar analyst.U.S. officials&nbsp;are expected to hold a press conference on autism on Monday; in the run-up, President Donald Trump had said: "We think we found an answer to autism... There's obviously something really wrong, we think we know what that is."The Washington Post reported on the weekend that officials will promote the drug leucovorin as a potential autism treatment. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.Earlier this month, the Wall Street Journal reported U.S. health officials' internal view regarding Tylenol. The news sent Kenvue's shares down 9.4% on Sept. 5. Kenvue said on Sunday that "independent, sound science" shows taking acetaminophen does not cause autism."We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers," the company said in a statement.Several Stocktwits users, on both Kenvue and J&amp;J&nbsp;streams, predicted steep declines for the stocks on Monday. Twenty-four-hour message volume on the tickers surging 300% and 150%, respectively.Retail sentiment for both KVUE and JNJ was ‘neutral’ at the time of writing, indicating significant levels of caution among traders ahead of Monday’s market open.<figure class="image"><img style="aspect-ratio:567/71;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_41_57_AM_png_e493de6988.webp" alt="Screenshot 2025-09-22 at 9.41.57 AM.png" width="567" height="71"><figcaption>KVUE sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:571/73;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_42_37_AM_png_11ece70092.webp" alt="Screenshot 2025-09-22 at 9.42.37 AM.png" width="571" height="73"><figcaption>JNJ sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure>"$JNJ 5-year chart looks like a heartbeat… she's gonna drop and flatline tomorrow," said a user.<stembedurl>https://stocktwits.com/TheDude5386/message/629455153</stembedurl>Another said: "$KVUE could be a buying opportunity if we see an overreaction."<stembedurl>https://stocktwits.com/Sigh_why/message/629453593</stembedurl>Kenvue's main brands include Tylenol, Motrin, Listerine, Neutrogena, Aveeno, and Band-Aid.<a href="https://stocktwits.com/symbol/KVUE">Kenvue shares</a> are down 14.1% year-to-date;&nbsp;<a href="https://stocktwits.com/symbol/JNJ">J&amp;J stock</a> is up 22%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-confirms-news-corp-s-murdochs-larry-ellison-michael-dell-lining-up-to-take-over-tik-tok-us/chDQBrbR3cR">Trump Confirms News Corp’s Murdochs, Larry Ellison, Michael Dell Lining Up To Take Over TikTok US</a>

Pain medications, which contain acetaminophen, are shown on April 14, 2015 in Chicago, Illinois. (Photo Illustration by Scott Olson/Getty Images)

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

KVUE
Kenvue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KVUE News

KVUE Kenvue Inc